We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

116 hedge funds and large institutions have $443M invested in BioCryst Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 45 increasing their positions, 23 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 23

57% more call options, than puts

Call options by funds: $907K | Put options by funds: $577K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

6.96% more ownership

Funds ownership: 84.81% → 91.78% (+7%)

1% more capital invested

Capital invested by funds: $439M → $443M (+$4.9M)

3% less funds holding

Funds holding: 120 → 116 (-4)

17% less first-time investments, than exits

New positions opened: 19 | Existing positions closed: 23

Holders
116
Holders Change
-4
Holders Change %
-3.33%
% of All Funds
2.63%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
19
Increased
45
Reduced
23
Closed
23
Calls
$907K
Puts
$577K
Net Calls
+$330K
Net Calls Change
+$4.06M

Top Buyers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
+$15.1M
2
DM
Deerfield Management
New York
+$10.8M
3
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$10.7M
4
BlackRock
BlackRock
New York
+$4.81M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
+$4.52M

Top Sellers

Rank Fund Capital Flow
1
ACA
Avoro Capital Advisors
New York
-$6.96M
2
Citadel Advisors
Citadel Advisors
Florida
-$6.76M
3
VMI
VHCP Management II
New York
-$3.31M
4
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$2.68M
5
GTC
Ghost Tree Capital
New York
-$2.62M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of New York Mellon
26
Bank of New York Mellon
New York
$2.28M +$456K +94,160 +25%
Alyeska Investment Group
27
Alyeska Investment Group
Illinois
$2.21M – – –
TCM
28
Tekla Capital Management
Massachusetts
$2.21M +$610K +126,000 +39%
Renaissance Technologies
29
Renaissance Technologies
New York
$1.95M +$822K +169,700 +75%
Morgan Stanley
30
Morgan Stanley
New York
$1.91M +$129K +26,565 +7%
EU
31
Emory University
Georgia
$1.88M +$115K +23,726 +7%
ACA
32
Avoro Capital Advisors
New York
$1.67M -$6.96M -1,437,704 -81%
Two Sigma Investments
33
Two Sigma Investments
New York
$1.43M +$905K +186,881 +179%
EAM
34
Eventide Asset Management
Massachusetts
$1.42M – – –
CAM
35
ClariVest Asset Management
California
$1.36M +$983K +202,867 +272%
TA
36
Teachers Advisors
New York
$1.33M +$330K +68,120 +34%
OAM
37
Oxford Asset Management
United Kingdom
$1.21M +$1.09M +225,428 +1,948%
EP
38
Eversept Partners
New York
$974K +$961K +198,319 New
Goldman Sachs
39
Goldman Sachs
New York
$901K -$859K -177,294 -49%
Swiss National Bank
40
Swiss National Bank
Switzerland
$841K – – –
Allianz Asset Management
41
Allianz Asset Management
Germany
$810K +$27.2K +5,614 +4%
Citigroup
42
Citigroup
New York
$764K +$617K +127,326 +451%
California State Teachers Retirement System (CalSTRS)
43
California State Teachers Retirement System (CalSTRS)
California
$758K +$128K +26,410 +21%
RA
44
Royce & Associates
New York
$707K – – –
California Public Employees Retirement System
45
California Public Employees Retirement System
California
$581K – – –
AA
46
ALPS Advisors
Colorado
$535K +$145K +29,841 +38%
VIA
47
Vident Investment Advisory
Georgia
$527K +$520K +107,275 New
New York State Common Retirement Fund
48
New York State Common Retirement Fund
New York
$500K +$87.2K +18,000 +21%
UBS Group
49
UBS Group
Switzerland
$493K -$67.3K -13,892 -12%
AllianceBernstein
50
AllianceBernstein
Tennessee
$488K – – –
1
2
3 4 5

BCRX Hedge Fund Activity: Q4 2017 in Review

116 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q4 2017, worth a combined $443M — up 1.1% from $439M a quarter earlier.

Sellers outnumbered buyers: 23 funds closed out of BCRX and 19 opened new positions — a net loss of 4 holders — while 23 trimmed existing stakes and 45 added.

The largest buyer was Great Point Partners, adding an estimated $15.1M. The largest seller was Avoro Capital Advisors, cutting an estimated $6.96M.

  • 116 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q4 2017, down from 120 in Q3 2017.
  • Funds reported $443M of BioCryst Pharmaceuticals stock for Q4 2017, up 1.1% quarter-over-quarter.
  • 19 funds opened new BioCryst Pharmaceuticals positions in Q4 2017 and 23 closed out, a net change of -4 holders.
  • The largest BioCryst Pharmaceuticals buyer in Q4 2017 was Great Point Partners, an estimated $15.1M added.
  • The largest BioCryst Pharmaceuticals seller in Q4 2017 was Avoro Capital Advisors, an estimated $6.96M sold.

Based on aggregated 13F filings for Q4 2017.